Dataset Information

In vitro human H9 ESC-derived microglia scRNA seq

ABSTRACT: Given that the γ-secretase substrate proteome identified in H9MG reveals its central role in microglial signaling-regulatory events, we reasoned that investigating the overall profile of the transcriptomes of the microglia would provide a good integrated read-out for the overall context-dependent effect of blocking the processing of >85 γ-secretase substrates. Although the alteration in tonic signaling caused by γ-secretase inhibition does not change the overall cell state, i.e. the cells with γ-secretase deficiency do not cluster dramatically differently in the UMAP plots (Figure 4E-F and J-K), the tonic signaling is robust as it remains discernible in the background of a strong LPS-induced response (Figure 4H and M).

ORGANISM(S): Homo sapiens

PROVIDER: GSE245330 | GEO | 2023/10/16

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Glucocorticoids are an essential component of the treatment of lymphoid malignancies and resistance to glucocorticoid therapy constitutes a prominent clinical problem in relapsed and refractory lymphoblastic leukemias. Constitutively active NOTCH signaling is involved in the pathogenesis of over 50% of T-cell lymphoblastic leukemia (T-ALL) which harbor activating mutations in the NOTCH1 gene. Aberrant NOTCH1 signaling has been shown to protect normal thymocytes from glucocorticoid induced cell death. Here we analyzed the interaction of glucocorticoid therapy with inhibition of NOTCH signaling in the treatment of T-ALL. Gamma-secretase inhibitors (GSI), which block the activation of NOTCH receptors, amplified the transcriptional changes induced by glucocorticoid treatment, including glucocorticoid receptor autoinduction and restored sensitivity to dexamethasone in glucocorticoid-resistant T-ALL cells. Apoptosis induction upon inhibition of NOTCH signaling and activation of the glucocorticoid receptor was dependent on transcriptional upregulation of BIM and subsequent activation of the mitochondrial/intrinsic cell death pathway. Finally, we used a mouse xenograft model of T-ALL to demonstrate that combined treatment with dexamethasone and a GSI results in improved antileukemic effects in vivo. These studies provide insight in the mechanisms of glucocorticoid resistance and serve as rationale for the use of glucocorticoid and GSIs in combination in the treatment of T-ALL. Experiment Overall Design: Duplicate samples (biologic replicas) from CUTLL1 cells were treated for 24 hours with vehicle only (DMSO), dexamethasone (1microM), a gamma-secretase inhibitor (CompE 100nM) and a combination of dexamethasome plus gamma secretase inhibitor at the same concentrations indicated before. Gene expression profiling was analyzed to identify gene expression signatures assocuated with glucocorticoid treatment (dexamethasone), inhibition of NOTCH1 by gamma secretase inhibitor (CompE) or the combination of both treatments.

Dataset Information

In vitro human H9 ESC-derived microglia scRNA seq

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets